The efficacy of aerosol treatment with non-ionic surfactant vesicles containing amphotericin B in rodent models of leishmaniasis and pulmonary aspergillosis infection

Journal of Controlled Release

Volumn 160, Issue 3, 2012, Pages 685-691

  Alsaadi, M ^a   Italia, J L ^a   Mullen, A B ^a   Kumar, M N V Ravi ^a   Candlish, A A ^b   Williams, R A M ^a   Shaw, C D ^a   Al Gawhari, F ^a   Coombs, G H ^a   Wiese, M ^a   Thomson, A H ^a   Puig Sellart, M ^a   Wallace, J ^a   Sharp, A ^c   Wheeler, L ^a   Warn, P ^c   Carter, K C ^a  

^a UNIVERSITY OF STRATHCLYDE   (United Kingdom)

^b GLASGOW CALEDONIAN UNIVERSITY   (United Kingdom)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Amphotericin B; Aspergillus; Inhalation; Leishmania; Non ionic surfactant vesicles

Indexed keywords

AMPHOTERICIN B; CLINICAL USE; HUMAN HEALTH; INHALATION; LEISHMANIA; LEISHMANIA MAJOR; NEBULISATION; NEPHROTOXICITY; PARASITE-; PARENTERAL ADMINISTRATION; PLASMA LEVELS; PULMONARY ASPERGILLOSIS; RAT MODEL; RODENT MODELS;

ASPERGILLUS; BIOMEDICAL ENGINEERING; CONTROLLED DRUG DELIVERY;

TOXICITY;

AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; DEXTRIN; GAMMA CYCLODEXTRIN; NONIONIC SURFACTANT; POSACONAZOLE;

AEROSOL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ANTIPROTOZOAL ACTIVITY; ARTICLE; BONE MARROW; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG DOSAGE FORM COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DRUG TISSUE LEVEL; EXPERIMENTAL MODEL; FEMALE; FREEZE DRYING; INHALATION SPACER; LEISHMANIA DONOVANI; LEISHMANIA MAJOR; LIVER; LUNG ASPERGILLOSIS; MEDICAL NEBULIZER; MOUSE; NEBULIZATION; NONHUMAN; PRIORITY JOURNAL; RAT; SKIN; SKIN LEISHMANIASIS; SPLEEN; VISCERAL LEISHMANIASIS;

AEROSOLS; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; CRICETINAE; DISEASE MODELS, ANIMAL; DRUG CARRIERS; FEMALE; FIREFLY LUCIFERIN; LEISHMANIASIS; LIVER; LUNG; MESOCRICETUS; MICE; MICE, INBRED BALB C; PULMONARY ASPERGILLOSIS; RATS; RATS, SPRAGUE-DAWLEY; SURFACE-ACTIVE AGENTS;

EID: 84861994530     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2012.04.004     Document Type: Article

References (26)

1. A. Gullo, Invasive fungal infections: the challenge continues, Drugs 69 (Suppl. 1) (2009) 65-73.
2. G. Matlashewski, B. Arana, A. Kroeger, S. Battacharya, S. Sundar, P. Das, P.K. Sinha, S. Rijal, D. Mondal, D. Zilberstein, J. Alvar, Visceral leishmaniasis: elimination with existing interventions, Lancet Infect. Dis. 11 (2011) 322-325.
3. B.E. Cohen, Amphotericin B membrane action: role for two types of ion channels in eliciting cell survival and lethal effects, J. Membr. Biol. 238 (2010) 1-20.
4. A.W. Ng, K.M. Wasan, G. Lopez-Berestein, Development of liposomal polyene antibiotics: an historical perspective, J. Pharm. Pharm. Sci. 6 (2003) 67-83. (Pubitemid 37207242)
5. S. Schwartz, G. Behre, V. Heinemann, et al., Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial, Blood 93 (1999) 3654-3661. (Pubitemid 29249811)
6. L. Kuiper, E.J. Ruijgrok, A review on the clinical use of inhaled amphotericin B, J. Aerosol Med. Pulm. Drug Deliv. 22 (2009) 213-227.
7. A.B. Mullen, K.C. Carter, A.J. Baillie, Comparison of the efficacies of various formulations of amphotericin B against murine visceral leishmaniasis, Antimicrob. Agents Chemother. 10 (1997) 2089-2092. (Pubitemid 27422195)
8. C. Chen, D. Han, C. Cai, X. Tang, An overview of liposome lyophilization and its future potential, J. Control. Release. 142 (2010) 299-311.
9. K.C. Carter, A.B. Mullen, S. Sundar, R.T. Kenney, Efficacies of vesicular and free sodium stibogluconate against clinical isolates of Leishmania donovani, Antimicrob. Agents Chemother. 45 (2001) 3555-3559. (Pubitemid 33107877)
10. A. Misslitz, J.C. Mottram, P. Overath, T. Aebischer, Targeted integration into a rRNA locus results in uniform and high level expression of transgenes in Leishmania amastigotes, Mol. Biochem. Parasitol. 107 (2000) 251-261. (Pubitemid 30211639)
11. J.L. Italia, D. Singh, M.N.V.R. Kumar, High-performance liquid chromatographic analysis of amphotericin B in rat plasma using a-naphthol as an internal standard, Anal. Chim. Acta 634 (2009) 110-114.
12. J.M. Lestner, S.J. Howard, J. Goodwin, L. Gregson, J. Majithiya, T.J. Walsh, G.M. Jensen, W.W. Hope, Pharmacokinetics and pharmacodynamics of amphotericin B deoxycholate, liposomal amphotericin B, and amphotericin B lipid complex in an in vitro model of invasive pulmonary aspergillosis, Antimicrob. Agents Chemother. 54 (2010) 3432-3441.
13. K.C. Carter, S. Hutchison, A. Boitelle, H.W. Murray, S. Sundar, A.B. Mullen, Sodium stibogluconate resistance in Leishmania donovani correlates with greater tolerance to macrophage antileishmanial responses and trivalent antimony therapy, Parasitology 131 (2005) 747-757. (Pubitemid 41772371)
14. D.C. Sheppard, et al., Standardization of an experimental murine model of invasive pulmonary aspergillosis, Antimicrob. Agents Chemother. 50 (2006) 3501-3503. (Pubitemid 44527538)
15. Y. Zhao, S. Park, P. Warn, R. Shrief, E. Harrison, D.S. Perlin, Detection of Aspergillus fumigatus in a rat model of invasive pulmonary aspergillosis by real-time nucleic acid sequence-based amplification, J. Clin. Microbiol. 48 (2010) 1378-1383.
16. X. Sun, R. Rossin, J.L. Turner, M.L. Becker, M.J. Joralemon, M.J. Welch, K.L. Wooley, An assessment of the effects of shell cross-linked nanoparticle size, core composition, and surface PEGylation on in vivo biodistribution, Biomacromolecules 6 (2005) 2541-2554. (Pubitemid 41388265)
17. T.J. Brown, B.R. Nelson, Melanoma: a clinical review, Cutis 63 (1999) 275-278.
18. W. Wong, J. Crapper, H.K. Chan, D. Traini, P.M. Young, Pharmacopeial methodologies for determining aerodynamic mass distributions of ultra-high dose inhaler medicines, J. Pharm. Biomed. Anal. 51 (2010) 853-857.
19. A.J. Ullmann, E. Krammes, S. Sommer, I. Buschmann, B. Jahn-Muehl, A. Cacciapuoti, H.J. Schmitt, Efficacy of posaconazole and amphotericin B in experimental invasive pulmonary aspergillosis in dexamethasone immunosuppressed rats, J. Antimicrob. Chemother. 60 (2007) 1080-1084. (Pubitemid 47617757)
20. A.C. Leenders, S. de Marie, M.T. ten Kate, I.A. Bakker-Woudenberg, H.A. Verbrugh, Liposomal amphotericin B (AmBisome) reduces dissemination of infection as compared with amphotericin B deoxycholate (Fungizone) in a rat model of pulmonary aspergillosis, J. Antimicrob. Chemother. 38 (1996) 215-225. (Pubitemid 26302582)
21. J. Gavaldà, T. Martín, P. López, X. Gomis, J.L. Ramírez, D. Rodríguez, O. Len, Y. Puigfel, I. Ruiz, A. Pahissa, Efficacy of high loading doses of liposomal amphotericin B in the treatment of experimental invasive pulmonary aspergillosis, Clin. Microbiol. Infect. 11 (2005) 999-1004. (Pubitemid 41748934)
22. R. Siekmeier, G. Scheuch, Treatment of systemic diseases by inhalation of biomolecule aerosols, J. Physiol. Pharmacol. 60 (Suppl. 5) (2009) 15-26.
23. P. Gershkovich, E.K. Wasan, M. Lin, O. Sivak, C.G. Leon, J.G. Clement, K.M. Wasan, Pharmacokinetics and biodistribution of amphotericin B in rats following oral administration in a novel lipid-based formulation, J. Antimicrob. Chemother. 64 (2009) 101-108.
24. S.J. Thornton, K.M. Wasan, The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis, Expert Opin. Drug Deliv. 6 (2009) 271-284.
25. E.K. Wasan, P. Gershkovich, J. Zhao, X. Zhu, K. Werbovetz, R.R. Tidwell, J.G. Clement, S.J. Thornton, K.M. Wasan, A novel tropically stable oral amphotericin B formulation (iCo-010) exhibits efficacy against visceral Leishmaniasis in a murine model, PLoS Negl. Trop. Dis. 4 (2010) e913.
26. Y. Niki, E.M. Bernard, H.J. Schmitt, W.P. Tong, F.F. Edwards, D. Armstrong, Pharmacokinetics of aerosol amphotericin B in rats, Antimicrob. Agents Chemother. 34 (2) (1990) 9-32.